Helene and Stephen Weicholz Cell Therapy Laboratory, Marcus Neuroscience Institute, 800 Meadows Road, Boca Raton, FL 33486, USA.
Department of Pathology and Laboratory Medicine, Center for Cancer Research, University of Tennessee Health Sciences Center, 920 Madison Ave., Memphis, TN 38163, USA.
Int J Mol Sci. 2023 May 23;24(11):9142. doi: 10.3390/ijms24119142.
Adaptive plasticity of Breast Cancer stem cells (BCSCs) is strongly correlated with cancer progression and resistance, leading to a poor prognosis. In this study, we report the expression profile of several pioneer transcription factors of the network associated with tumor initiation and metastasis. In the triple negative breast cancer cell line (MDA-MB-231) stably transfected with human Oct3/4-GFP, differentially expressed genes (DEGs) were identified using qPCR and microarray, and the resistance to paclitaxel was assessed using an MTS assay. The tumor-seeding potential in immunocompromised (NOD-SCID) mice and DEGs in the tumors were also assessed along with the intra-tumor (CD44+/CD24-) expression using flow cytometry. Unlike 2-D cultures, the Oct3/4-GFP expression was homogenous and stable in 3-D mammospheres developed from BCSCs. A total of 25 DEGs including and were identified in Oct3/4 activated cells coupled with a significantly increased resistance to paclitaxel. In mice, the higher Oct3/4 expression in tumors correlated with enhanced tumorigenic potential and aggressive growth, with metastatic lesions showing a >5-fold upregulation of DEGs compared to orthotopic tumors and variability in different tissues with the highest modulation in the brain. Serially re-implanting tumors in mice as a model of recurrence and metastasis highlighted the sustained upregulation of and genes in metastatic lesions with a 2-fold higher expression of stem cell markers (CD44+/CD24-). Thus, transcriptome may drive the differentiation and maintenance of BCSCs, promoting their tumorigenic potential, metastasis and resistance to drugs such as paclitaxel with tissue-specific heterogeneity.
乳腺癌干细胞(BCSCs)的适应性可塑性与癌症进展和耐药性密切相关,导致预后不良。在这项研究中,我们报告了与肿瘤起始和转移相关的网络的几个先驱转录因子的表达谱。在稳定转染人 Oct3/4-GFP 的三阴性乳腺癌细胞系(MDA-MB-231)中,使用 qPCR 和微阵列鉴定差异表达基因(DEGs),并使用 MTS 测定评估紫杉醇的耐药性。还评估了在免疫缺陷(NOD-SCID)小鼠中的肿瘤播种潜力以及肿瘤中的 DEGs,以及使用流式细胞术评估肿瘤内(CD44+/CD24-)表达。与 2-D 培养物不同,Oct3/4-GFP 在从 BCSCs 发育而来的 3-D 乳腺球体中的表达是同质和稳定的。在激活的 Oct3/4 细胞中鉴定出总共 25 个 DEGs,包括 和 ,同时对紫杉醇的耐药性显著增加。在小鼠中,肿瘤中更高的 Oct3/4 表达与增强的致瘤潜能和侵袭性生长相关,与原位肿瘤相比,转移性病变中 DEGs 的上调幅度超过 5 倍,并且在不同组织中存在变异性,其中在大脑中的调制最高。作为复发和转移模型的小鼠中肿瘤的连续再植入突出了转移性病变中 和 基因的持续上调,干细胞标志物(CD44+/CD24-)的表达增加了 2 倍。因此,转录组可能驱动 BCSCs 的分化和维持,促进其致瘤潜能、转移和对紫杉醇等药物的耐药性,具有组织特异性异质性。